Bionetworks: reviewing the various collaborations between pharma, biotech, academia and venture capitalists
Posted: 29 May 2014 | SMI Group | No comments yet
Companies are realizing that their own internal R&D groups alone are not enough and as pharma groups slash their internal R&D projects…
Companies are realizing that their own internal R&D groups alone are not enough and as pharma groups slash their internal R&D projects, they have taken a shining to funding discovery and early R&D work with outside sources. This is therefore impacting on the expansion and number of collaborations with academics and other external groups.
Based on this information, the SMi Group is delighted to introduce its inaugural European Bionetworks Summit, taking place in London, UK, on the 7th and 8th of July 2014. The event programme includes timely case studies, presentations, roundtables and panel discussions on the hottest topics, delivered by leading industry experts as they demonstrate how to create winning strategic partnerships from modern day collaborations. This unique event will create the perfect platform for Pharmaceutical, Biotech, Academia and Venture Capitalists to discuss the importance of creating winning strategic partnerships.
Event’s website: http://www.smi-online.co.uk/bio-networks47.asp
Event speakers include: Sanj Singh (President & CEO), AdeTherapeutics Inc; Mika Partanen (Deputy Director, Global Competitive Insights) Bayer Pharma; Robert Williams (Chief Development Scientist, Drug Development Office), Cancer Research UK; Jorgen Drejer (Chief Executive Officer), Aniona; Timothy Herpin (Head of Transactions (UK), Business Development), AstraZeneca; Dimitri Dimitriou (Chief Executive Officer, ImmuPharma, & Managing Partner), DyoDelta Biosciences; Joseph Sweeney (Professor of Catalysis and Chemical Biology, Department of Chemical Sciences), University of Huddersfield; Simone Breitkopf (Head Governmental and Public Affairs, Pricing and Reimbursement), Alcon Pharma GmbH; Mark Eccleston (External Collaborations Manager), Volition RX; Diane Harbison (Head of Business Development, Edinburgh Bioquarter), The University of Edinburgh; Michael Meyers (Vice President of Scientific Innovation, Oncology), Johnson & Johnson; Lubor Gaal (Head of Europe, Business Development), Bristol-Myers Squibb; Davidson Ateh (Chief Executive Officer), BioMoti; Adrian Dawkes (Vice President), PharmaVentures; Patrick Tricoli (Global R&D, External Innovation, Scouting and Partnering International), Sanofi S A; Colin Fishwick, Head of Organic Chemistry, School of Chemistry, University of Leeds; Eddie Blair (Chief Executive Officer), GeneFirst Ltd.
Interactive half-day post-conference workshop “Cost Effective Pathway to Early Clinical Development to Support Regulatory Approvals and Commercial Partnering” will be taking place on the 9th of July. Workshop Leaders: Carla Bennett, Senior Clinical Research Consultant, and Dr. Sarah Nicholson, Senior Regulatory Consultant, QRC Consultants Ltd.
For more information about this event please visit http://www.smi-online.co.uk/bio-networks53.asp
Sponsorship enquiries, please contact Alia Malick, Director, on +44(0) 207 827 6168 or e-mail [email protected]